VYNE Therapeutics Inc. (VYNE)
VYNE moved a median of 0.00% 30 minutes after news, and +0.16% by the close. How VYNE actually reacts to news — the realized, point-in-time move the market made, measured across 222 labeled events over the last three years with zero look-ahead.
VYNE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 205 |
| 30-min | 0.00% | 47% | 213 |
| 60-min | -0.62% | 44% | 214 |
| to close | +0.16% | 51% | 218 |
| Middle 50% of VYNE reactions | -1.73% to +1.59% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 222 |
Half of all VYNE Therapeutics Inc. news events land between -1.73% and +1.59% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VYNE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VYNE's baseline. Nothing else.
Recent VYNE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience | Press release | GlobeNewswire | +1.19% | +4.58% | |
| VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience | Press release | GlobeNewswire | +5.00% | +13.87% | |
| Form 8-K VYNE Therapeutics Inc. For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +5.00% | +13.87% | |
| Form 8-K VYNE Therapeutics Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +2.84% | +4.91% | |
| Form 8-K VYNE Therapeutics Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +2.46% | +9.38% | |
| Form 8-K VYNE Therapeutics Inc. For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +0.39% | |
| VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience | Press release | GlobeNewswire | +0.85% | +0.39% | |
| Form EFFECT VYNE Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.11% | -1.67% | |
| Form ARS VYNE Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.69% | +0.02% | |
| Form S-4/A VYNE Therapeutics Inc. | SEC filing · Form S-4 | SEC EDGAR | +0.63% | -2.10% | |
| Form 8-K VYNE Therapeutics Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.53% | |
| Form 10-Q VYNE Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.39% | +0.94% | |
| Form S-4/A VYNE Therapeutics Inc. | SEC filing · Form S-4 | SEC EDGAR | +0.00% | +0.94% | |
| Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | +0.00% | -0.82% | |
| Form S-4 VYNE Therapeutics Inc. | SEC filing · Form S-4 | SEC EDGAR | -1.65% | +1.00% | |
| Form 8-K VYNE Therapeutics Inc. For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | — | -2.10% | |
| Form 10-K VYNE Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.53% | +1.44% | |
| Form 8-K VYNE Therapeutics Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | +3.10% | |
| Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights | Press release | GlobeNewswire | +0.65% | +0.30% | |
| Form 8-K VYNE Therapeutics Inc. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -3.49% | -14.29% | |
| VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders | Press release | Business Wire | +0.30% | -3.69% | |
| VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement | Press release | GlobeNewswire | -3.49% | -14.29% | |
| Form 8-K VYNE Therapeutics Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.85% | |
| Form ARS VYNE Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.54% | — | |
| Form DEF 14A VYNE Therapeutics Inc. For: Dec 12 | SEC filing · Form DEF | SEC EDGAR | +3.54% | — | |
| Form 10-Q VYNE Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.67% | -2.14% | |
| Form 8-K VYNE Therapeutics Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | +2.44% | |
| VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.39% | +2.44% | |
| Form 8-K VYNE Therapeutics Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | -1.39% | |
| Form 10-Q VYNE Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.91% | +3.18% | |
| Form 8-K VYNE Therapeutics Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +0.69% | |
| VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.89% | +0.69% | |
| Form 8-K VYNE Therapeutics Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +2.26% | +0.68% | |
| VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo | Press release | GlobeNewswire | +2.77% | +0.75% | |
| VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | Press release | GlobeNewswire | -1.51% | -9.04% | |
| Form 10-Q VYNE Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.57% | +2.36% | |
| Form 8-K VYNE Therapeutics Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -2.83% | -7.80% | |
| VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.83% | -7.80% | |
| VYNE Therapeutics Provides Update on VYN202 Program | Press release | GlobeNewswire | -2.74% | -2.06% | |
| VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference | Press release | GlobeNewswire | +0.00% | -5.08% | |
| Form 10-K VYNE Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.52% | |
| Form 8-K VYNE Therapeutics Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | — | +0.43% | |
| VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update | Press release | GlobeNewswire | — | +0.43% | |
| VYNE Therapeutics to Participate in March Investor Conferences | Press release | GlobeNewswire | +3.21% | +8.43% | |
| VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis | Press release | GlobeNewswire | — | +1.61% | |
| Form 8-K VYNE Therapeutics Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -2.64% | -11.18% | |
| VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo | Press release | GlobeNewswire | +2.57% | +14.29% | |
| Form 8-K VYNE Therapeutics Inc. For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +1.73% | -1.15% | |
| VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | Press release | GlobeNewswire | +1.73% | -1.15% | |
| Form S-8 VYNE Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.67% | +4.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VYNE section they belong to.
Where else VYNE is measured.
VYNE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is VYNE Therapeutics Inc.'s median reaction calculated?
Every labeled VYNE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 222 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of VYNE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VYNE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.